NEW YORK (GenomeWeb News) – BioTrove and Gene Express have struck an agreement to co-market a test for profiling certain indicators for the risk of lung cancer, BioTrove said today.
The test, called the Standardized NanoArray PCR, or SNAP, gene expression profiling system, uses BioTrove’s OpenArray nanofluidic PCR platform, Gene Express’ PCR measurement standards, and clinical knowledge from the University of Rochester School of Medicine and Dentistry.
The PCR analysis profiling system is a novel method for “consistent and accurate lung cancer risk analysis” that may be used in diagnostic laboratories or community hospitals, BioTrove said.
David Lester, Gene Express’ chief technology officer, said in a statement that the SNAP system “simplifies and standardizes” lab workflows and makes “genetic profiling viable and translatable” in diagnostic labs.
BioTrove’s OpenArray system allows scientists to conduct up to 3,072 independent PCR analyses simultaneously on up to 144 samples in a single plate, while Gene Express’ Standardized RT PCR, or StaRT-PCR, control for false negatives and false positives, BioTrove said.